Abstract Background: Alpha-fetoprotein (AFP) is a well-identified biomarker in hepatocellular
carcinoma (HCC). However, only limited AFP-related studies have evaluated its early …

Background and aims The role of Alfa-fetoprotein (AFP) in the management of
hepatocellular carcinoma (HCC) is still debated, with differences in recommendations …

Background: Post-treatment alpha-fetoprotein (AFP) response has been reported to be
associated with prognosis of hepatocellular carcinoma (HCC) patients, but the results were …

Background and Objectives: Serum alpha-fetoprotein (AFP) is a recognized affordable
oncological marker in patients with hepatocellular carcinoma (HCC). However, AFP's …

Background. The role of serum α-fetoprotein (AFP) as a marker for treatment response in
patients with hepatocellular carcinoma (HCC) receiving systemic therapy is poorly defined …

Objective: AFP has been used as a surveillance tool for HCC recurrence, but the prognostic
utility of an elevated pretreatment AFP level is poorly defined. This review sought to analyze …

BACKGROUND: Antiangiogenic therapy has become the most important treatment modality
for patients with advanced hepatocellular carcinoma (HCC). In this study, the authors …

Background Hepatocellular carcinoma is one of the most lethal cancers worldwide. Novel
prognostic and/or predictive biomarkers are urgently needed to improve patient …

Background Alpha-fetoprotein (AFP) expression is closely related to hepatocarcinogenesis,
and it is an important prognostic factor for hepatocellular carcinoma (HCC). We aimed to …

Background: Serum alpha-fetoprotein (AFP) is an important clinical indicator for screening,
diagnosis, and prognosis of primary hepatocellular carcinoma (HCC). Our team's previous …